NASDAQ · LFWD

Lifeward Ltd.

$7.11 +$0.06 (+0.90%) 1D Market open

Key Metrics

$19.84M
Market cap
P/E · TTM
$20.92M
Revenue · TTM
−$25.87M
Net income
EPS · TTM $-29.61
Dividend yield
Free cash flow −$15.02M
Beta · 1Y 1.17
EBITDA · TTM −$25.63M
Gross margin 36.6%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 25
    The stock moved +20.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 25
  • Feb 23
    From its Jan 29 high, the share price fell 38%.

    Peak close $7.44 on Jan 29; trough close $4.59 on Feb 23. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -38%
  • Feb 20
    The stock moved -18.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 20

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$19.84M
Enterprise value
Shares outstanding2.8M
52-wk range$0.51 – $9.61
Avg volume · 20D424.4K
Net cash
Book value / share$7.20
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
ExchangeNASDAQ
About Lifeward Ltd.
IPO dateSep 12, 2014
Employees81

Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions spanning the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.95
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 36.6%
Operating -123.9%
Net -123.7%
FCF -71.8%
ROE / ROIC -205.8% · 504.2%

Financial Health

Current ratio2.40
Quick ratio1.82
Debt / equity
Debt / EBITDA
Net cash
Working capital$14.92M

Cash Flow · TTM

Operating CF −$15.01M
Capex −$11.00K
Free cash flow −$15.02M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-13.3
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings